In the work of new drug R&D, registration application, and marketing, three types of drug protection cycles are easily confused: Patent Term Compensation (PTE), Drug Trial Data Protection Period, and Drug Market Exclusivity Period.

Many people think these three are all “protection periods,” but their essence is completely different:

Patents protect technology—others cannot use your molecular structure;

The data protection period protects the data—others can’t use your clinical trial results for free;

The market exclusivity period protects the market itself—directly prohibiting the launch and sale of competing products, regardless of whether the technology or data is independently completed.

All three together determine the same question: how many years can a drug remain exclusive in the market after its patent expires?

Today, let’s break down these three types of protection periods one by one.

---

1. Patent Term Compensation (PTE)

1. Core definition

The statutory protection period for invention patents in China is 20 years, automatically starting from the patent application date, not starting after the drug is marketed.

In contrast, the R&D cycle for innovative drugs generally lasts 8 to 12 years. During this long process of research and approval, patents were counted down, but the drugs could never be launched or sold or generate any commercial profit.

Patent validity periods are heavily consumed during R&D approvals, and drugs enter the end of their patents by the time they are launched—this is precisely the problem PTE aims to solve.

To this end, the state has specially established a patent term compensation system (PTE). For innovative drugs that have already been approved for marketing, provided legal rules are met, the National Intellectual Property Administration may extend the protection period for core invention patents to compensate for patent time lost due to clinical trials and administrative approvals, allowing innovative drug companies to have a reasonable and sufficient patent exclusivity cycle.

2. Compensation rules

The compensation period shall not exceed 5 years

The total effective patent term after new drug approval and marketing does not exceed 14 years

If a drug has multiple patents simultaneously, the patent holder can only request compensation for one of the patents

Types of patents eligible for compensation include: product invention patents for active pharmaceutical substances, invention patents for preparation methods, and invention patents for pharmaceutical uses.

Improved new drugs eligible for compensation are limited to the following categories:

Class 2.1 of chemical drugs (esters or salts of known active ingredients)

Class 2.4 Chemical Drugs (New Indication)

Therapeutic Biologics Class 2.2 (New Indication)

Traditional Chinese Medicine Class 2.3 (Newly Added Functions and Indications)

---

3. Compensation duration calculation logic

Let’s use a concrete example to illustrate this calculation logic:

Starting from the filing date, the statutory term of a patent is 20 years. It took six years to conduct clinical trials for a single drug, and another two years to get approved, resulting in a total delay of eight years. The 20-year patent term still has 12 years left.

The compensation period for drug patent rights = drug D’s marketing authorization date – D’s patent application date-5(≦5 years).

The law stipulates that the maximum period cannot exceed 5 years! Assuming compensation is compensated according to a 5-year patent term, the time should be 12 + 5 = 17 years,

But:

The total validity period after listing must not exceed 14 years, so the actual compensation period can only be supplemented for 2 years, and the post-compensation validity period is 14 years.

2. Drug trial data protection period

1. Core definition

Data protection means that when eligible chemical drugs and biological products are approved for marketing, the National Medical Products Administration protects experimental data and other data submitted by the applicant for self-obtained and undisclosed data, granting a data protection period of up to 6 years.
Simply put: I spent billions to create clinical data, and you can’t use it for nothing.
During the protection period, if other applicants rely on protected data to apply for drug marketing without the consent of the marketing authorization holder, the National Medical Products Administration will not grant approval.

2. Protection period

In May 2026, the “Implementation Measures for Data Protection in Drug Trials” will officially come into effect, clarifying the data protection periods for different drugs:
In addition to the basic classifications above, there is a special rule worth noting: for original drug drugs that have been marketed overseas but not yet marketed domestically, if a new global indication registration application is submitted in China for the first time, the data protection period for that indication is 6 years; For subsequent new indications, the period is 4 years.

3. Drug market monopoly period

1. Core definition

The drug market monopoly period is when drug regulatory authorities grant exclusive administrative rights to the drug marketing authorization holder in the terminal market. Within the prescribed protection period, even if a peer independently completes a full set of clinical trials and all drug reviews are qualified, regulatory authorities will not approve the launch and sale of similar competing products, directly isolating market competition.

In short, no matter what drug the other party is preparing, during the protection period, the same type of drug must not be sold on the market.

2. Three types

Type 1: First-Generic Market Monopoly Period (12 months)

According to Article 11 of the “Implementation Measures for the Early Resolution Mechanism of Pharmaceutical Patent Disputes”:

For the first chemical generic drug successfully challenged and approved for market launch, a market exclusivity period will be granted. The drug regulatory authority under the State Council shall no longer approve the marketing of generic drugs of the same type within 12 months from the date of approval. It should be noted that the 12-month exclusivity period mainly applies to newly submitted generic drug applications of the same product type during the exclusive period, which will not be approved.

Simply put: obtaining market exclusivity = successful patent challenge for the first time + first approval for listing

Type 2: Medication for rare diseases (no more than 7 years)

According to Article 21 of the Regulations for the Implementation of the Drug Administration Law (2026 revision):

For drugs used for rare disease treatment that meet the conditions, if the marketing authorization holder commits to ensuring drug supply, a market exclusivity period of up to 7 years shall be granted. If the drug marketing authorization holder fails to fulfill the commitment to ensure drug supply, the market exclusivity period will be terminated.

Type 3: Medication for children (no more than 2 years)

According to Article 21 of the Regulations for the Implementation of the Drug Administration Law (2026 revision):

For new varieties of pediatric drugs, drugs adopting new dosage forms or specifications, or drugs with added indications for children, if conditions are met, a market exclusivity period of up to 2 years shall be granted.

Classification	Applicable Situations	Protection period
Category 1	Innovative drugs not yet marketed domestically or internationally	6 years
Category 2	Improved new drugs not yet marketed domestically or internationally	4 years
Category 3	The first approved generic drug that has been marketed overseas but has not yet been marketed domestically	3 years
Category 4	Generic original drugs already marketed domestically	No provisions
5.1	Original research drugs listed overseas apply for domestic listing	6 years
5.1	Improved drugs marketed overseas apply for domestic listing	4 years
5.2	Generic drugs that have been listed overseas but not yet marketed domestically apply for domestic listing	3 years

4. A single table thoroughly distinguishes these three categories

Contrast dimensions	Patent term compensation	Data protection period	Market exclusivity period
Protected objects	Technical solution	Clinical trial data	Drug sales activities
Legal basis	Patent Law	Implementation Measures for Data Protection in Drug Trials	Regulations for the Implementation of the Drug Administration Law
Regulatory Entities	National Intellectual Property Administration	National Medical Products Administration	National Medical Products Administration
Time limit	Up to 5 years	Innovative drugs for 6 years	Rare disease 7 years / pediatric drug 2 years / first generic 12 months

5. Conclusion

A drug can enjoy all three protections simultaneously: core compound patents receive patent term compensation, with a maximum patent period of 14 years after market launch; Innovative drugs are eligible for a 6-year data protection period; Rare disease recognition can also be combined with a 7-year market exclusivity period.

PTE management drug technology, data protection management clinical applications, and market-exclusive terminal sales. These three do not conflict with each other and can be stacked simultaneously, forming differentiated protection across technology, registration, and market layers. Accurately distinguishing these three types of information is the foundation for reasonably planning the payback cycle of new drug development and assessing the full lifecycle value of a drug.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.